Esketamine Sintetica 25 mg/ml solution for injection/infusion Ireland - English - HPRA (Health Products Regulatory Authority)

esketamine sintetica 25 mg/ml solution for injection/infusion

sintetica gmbh - esketamine hydrochloride - solution for injection/infusion - esketamine

Esketamine Sintetica 5 mg/ml solution for injection/infusion Ireland - English - HPRA (Health Products Regulatory Authority)

esketamine sintetica 5 mg/ml solution for injection/infusion

sintetica gmbh - esketamine hydrochloride - solution for injection/infusion - esketamine

SPRAVATO- esketamine hydrochloride solution United States - English - NLM (National Library of Medicine)

spravato- esketamine hydrochloride solution

janssen pharmaceuticals inc. - esketamine hydrochloride (unii: l8p1h35p2z) (esketamine - unii:50lfg02txd) - spravato ® is indicated, in conjunction with an oral antidepressant, for the treatment of: - treatment-resistant depression (trd) in adults - depressive symptoms in adults with major depressive disorder (mdd) with acute suicidal ideation or behavior limitations of use: - the effectiveness of spravato in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated [see clinical studies (14.2)] . use of spravato does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of spravato. - spravato is not approved as an anesthetic agent. the safety and effectiveness of spravato as an anesthetic agent have not been established. spravato is contraindicated in patients with: - aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels) or arteriovenous malformation [see warnings and precautions (5.7)] - history of intracere

Esketamine Kalceks 5 mg/ml inj./inf. sol. i.v./i.m. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

esketamine kalceks 5 mg/ml inj./inf. sol. i.v./i.m. amp.

as kalceks a.s. - esketamine hydrochloride 5,77 mg/ml - eq. esketamine 5 mg/ml - solution for injection/infusion - 5 mg/ml - esketamine hydrochloride 5.77 mg/ml - esketamine

Esketamine Kalceks 25 mg/ml inj./inf. sol. i.v./i.m. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

esketamine kalceks 25 mg/ml inj./inf. sol. i.v./i.m. amp.

as kalceks a.s. - esketamine hydrochloride 28,85 mg/ml - eq. esketamine 25 mg/ml - solution for injection/infusion - 25 mg/ml - esketamine hydrochloride 28.85 mg/ml - esketamine

Esketamine Kalceks 25 mg/ml inj./inf. sol. i.v./i.m. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

esketamine kalceks 25 mg/ml inj./inf. sol. i.v./i.m. amp.

as kalceks a.s. - esketamine hydrochloride 28,85 mg/ml - eq. esketamine 25 mg/ml - solution for injection/infusion - 25 mg/ml - esketamine hydrochloride 28.85 mg/ml - esketamine

Esketamine Sintetica 25 mg/ml solution for injection/infusion Ireland - English - HPRA (Health Products Regulatory Authority)

esketamine sintetica 25 mg/ml solution for injection/infusion

sintetica ireland limited - esketamine - solution for injection/infusion - 25 milligram(s)/millilitre - esketamine

Esketamine Sintetica 5 mg/ml solution for injection/infusion Ireland - English - HPRA (Health Products Regulatory Authority)

esketamine sintetica 5 mg/ml solution for injection/infusion

sintetica ireland limited - esketamine - solution for injection/infusion - 5 milligram(s)/millilitre - esketamine

SPRAVATO esketamine (as hydrochloride) 28 mg per 2 actuations nasal spray solution Australia - English - Department of Health (Therapeutic Goods Administration)

spravato esketamine (as hydrochloride) 28 mg per 2 actuations nasal spray solution

janssen-cilag pty ltd - esketamine hydrochloride, quantity: 32.3 mg (equivalent: esketamine, qty 28 mg) - spray, nasal - excipient ingredients: disodium edetate; citric acid monohydrate; water for injections; sodium hydroxide - spravato is indicated for treatment resistant depression (major depressive disorder in adults who have not responded adequately to at least two different antidepressants of adequate dose and duration to treat the current moderate to severe depressive episode).,spravato is to be initiated in conjunction with a newly initiated oral antidepressant.

SPRAVATO SOLUTION Canada - English - Health Canada

spravato solution

janssen inc - esketamine (esketamine hydrochloride) - solution - 28mg - esketamine (esketamine hydrochloride) 28mg - miscellaneous antidepressants